In patients undergoing surgery for colorectal cancer, a technique delivering local anesthetic directly to the surgical wound not only helps to control postoperative pain but also reduces recovery time.
The University of Illinois at Chicago is one of 16 sites in the United States taking part in the first large-scale study to test a promising approach to lowering blood glucose levels in adults with type 2 diabetes.
A new report from a team of researchers at the University of Washington, Seattle, and the University of Alabama at Birmingham indicates that one of the main complications of liver transplantation can be treated very simply by allowing the transplant recipients to inhale nitric oxide (NO) during the operation in which they received their new liver.
The U.S. Food and Drug Administration approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.
New research by scientists in Taiwan has shown that an 800-year-old formula, Four-Agents Decoction (Si Wu Tang), does not significantly reduce menstrual pain after three cycles of treatment; however, a beneficial effect may be present after a longer treatment.
Reclast? (zoledronic acid) Injection has been approved by the US Food and Drug Administration as the first and only once-yearly medicine for postmenopausal osteoporosis, offering an important new approach to the treatment of a bone disease affecting eight million women in the US.
Findings from a study released revealed that a limited amount of clinical research exists to prove the effectiveness of many over-the-counter (OTC) anti-aging products.
An investigational drug called ecallantide (also known as DX-88 [Dyax Corp., Cambridge, MA]) significantly relieves attacks of a rare, life-threatening disease called hereditary angioedema, report researchers from Children’s Hospital Boston and 25 other study sites.
Prescribing ambulatory oxygen in patients with chronic obstructive pulmonary disease improves exercise performance, but not the quality of their daily life unless they have resting hypoxemia, according to researchers in Toronto.
Based on an interim blinded analysis of the first group of the more than 80 patients who have now completed the trial at 16 weeks, the study has shown improvement in polyposis by endoscopy in about 50 percent of patients (N=43) and improvement in sinus inflammation by CT scan in approximately 50 percent of patients (N=23). Moreover, 50 percent of patients with objective evidence of improvement have achieved the primary endpoint of complete resolution of cardinal symptoms.